Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
CHAPEL HILL, N.C., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the 34th Annual J.P. Morgan Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is scheduled to present at 4:30 p.m. PT (7:30 p.m. ET) on Wednesday, January 13, 2016 in San Francisco.
A live audio webcast and archive of the presentation will be available on the company website at http://investor.cempra.com/events.cfm. Listeners are encouraged to visit the site prior to the scheduled presentation to register, download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) has successfully completed two Phase 3 clinical trials for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin is also in a Phase 3 clinical trial for uncomplicated urogenital urethritis caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra's second product candidate, which is being developed for acute bacterial skin and skin structure Infections (ABSSSI) and is also expected to be tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
CONTACTS: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 [email protected] Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 [email protected]
